RC118 + RC148

RC118 + RC148 is a combination therapy under clinical investigation for the treatment of advanced and unresectable or metastatic solid tumors, especially those with positive Claudin 18.2 expression. RC118 is an antibody-drug conjugate (ADC) developed to target Claudin 18.2, a tight junction protein highly expressed in certain cancers, including gastric and pancreatic cancers. RC148 is a bispecific antibody that inhibits both programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), acting as both an immune checkpoint inhibitor and an angiogenesis inhibitor. The combination aims to take advantage of targeted cytotoxic delivery (RC118) and simultaneous immune modulation and anti-angiogenesis (RC148), potentially increasing antitumor efficacy in solid tumors[6][4][5][7].